44
Participants
Start Date
September 25, 2017
Primary Completion Date
July 20, 2022
Study Completion Date
July 20, 2022
HYQVIA
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Northwell Health, Inc. PRIME, Great Neck
Stony Brook Children's Hospital, Stony Brook
Women & Children's Hospital of Buffalo, Buffalo
Section on Immunopathogenesis and Clinical Immunology, Fairfax
Marshall University Joan C. Edwards School of Medicine, Charleston
Carolinas Healthcare System, Charlotte
Allergy Asthma & Immunology Relief of Charlotte, Charlotte
Emory Healthcare, Atlanta
Georgia Pollens Clinical Research Centers, Inc., Albany
University of Miami Pediatric Allergy and Immunology, Miami
University of South Florida Physician Group, St. Petersburg
University of Alabama Medical Center, Birmingham
Washington University, St Louis
OK Institute of Allergy & Asthma Clinical Research, LLC, Oklahoma City
Vital Prospects Clinical Research Institute, P.C., Tulsa
Allergy Partners of North Texas Research, Dallas
University of Utah, Salt Lake City
Connecticut Children's Medical Center, Hartford
Boston Children's Hospital, Boston
Baxalta Innovations GmbH, now part of Shire
INDUSTRY
Baxalta now part of Shire
INDUSTRY